Who is sponsoring NCT04980950?

NCT04980950 is sponsored by Medical University of Gdansk.

What condition does NCT04980950 study?

NCT04980950 studies Gastric Cancer, Colorectal Cancer.

Is NCT04980950 still recruiting?

NCT04980950 is currently status unknown. Last updated 30 July 2021.

Last reviewed 2021-07-30 · How we verify

NCT04980950

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

"The Impact of Immunonutrition on Gut Microbiota-related Aspects in Colorectal Cancer and Gastric Cancer Patients"

Status unknown NA Last updated 30 July 2021

What this trial tests

NA trial testing Impact Oral Nestlé Health Science, Cubitan® Nutricia, Nutridrink® Nutricia, Resource 2.0 Nestlé Health Science in Gastric Cancer in 80 participants. Status unknown.

Timeline

1 August 2021

Primary endpoint
1 June 2022

1 July 2022

Quick facts

Lead sponsor	Medical University of Gdansk
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	80
Start date	1 August 2021
Primary completion	1 June 2022
Estimated completion	1 July 2022

Drugs / interventions tested

Impact Oral Nestlé Health Science, Cubitan® Nutricia, Nutridrink® Nutricia, Resource 2.0 Nestlé Health Science

Conditions studied

Gastric Cancer — all drugs for Gastric Cancer →
Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

Medical University of Gdansk

Who can join

Adults 18 to 80, any sex, with Gastric Cancer or Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Enteral immunomodulating nutrition modifies the gastrointestinal microbiota as well as improves the intestinal barrier integrity in patients with gastric and colorectal cancer in the perioperative period. As a consequence, it contributes to the reduction of the incidence of postoperative complications and diarrhea, which is a side effect of anti-cancer treatment often used preoperatively in this group of cancers.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Pancreatic Cancer and Gut Microbiome-Related Aspects: A Comprehensive Review and Dietary Recommendations.
Sobocki BK, Kaźmierczak-Siedlecka K, Folwarski M, Hawryłkowicz V, et al · · 2021 · cited 30× · PMID 34959977 · DOI 10.3390/nu13124425
Interdisciplinary insights into the link between gut microbiome and gastric carcinogenesis-what is currently known?
Kaźmierczak-Siedlecka K, Daca A, Roviello G, Catalano M, et al · · 2022 · cited 28× · PMID 34741681 · DOI 10.1007/s10120-021-01260-y
Bidirectional effects of intestinal microbiota and antibiotics: a new strategy for colorectal cancer treatment and prevention.
Zhang W, Zhang J, Liu T, Xing J, et al · · 2022 · cited 10× · PMID 35661254 · DOI 10.1007/s00432-022-04081-3
The role of intestinal flora on tumor immunotherapy: recent progress and treatment implications.
Zhou Y, Liu X, Gao W, Luo X, et al · · 2024 · cited 5× · PMID 38223735 · DOI 10.1016/j.heliyon.2023.e23919
The impact of enteral immunonutrition on gut microbiota in colorectal cancer and gastric cancer patients in the preoperative period-preliminary results of randomized clinical trial.
Kaźmierczak-Siedlecka K, Stachowska E, Kucharski R, Wiśniewski P, et al · · 2025 · cited 1× · PMID 40852731 · DOI 10.3389/fimmu.2025.1606187

Verify or expand the search:

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting

Other Medical University of Gdansk trials

Trials by the same sponsor.

NCT07521280 — State-Based Rehabilitation for Youth Athletes With Osgood-Schlatter or Sever-Related Apophyseal Pain · NA · not yet recruiting
NCT07446517 — Low-Level Laser Therapy for Osgood-Schlatter or Sever Pain in Youth Athletes · NA · recruiting
NCT07449585 — Pericapsular Nerve Group Block Versus Intrathecal Morphine for Analgesia After Total Hip Arthroplasty · NA · not yet recruiting
NCT07397208 — Assessment of the Repeatability of Sublingual Microcirculation Function Measurements in Healthy Volunteers and Criticall · not yet recruiting
NCT07345403 — GENECARD - the Use of Genetic, Epigenetic, Metabolomic, Proteomic and Microbiotic Markers, Image and Voice Biomarker Ana · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04980950 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Gdansk
Last refreshed: 30 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04980950.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing